Advertisement
Genmab A/S

Genmab A/S (GNMSF) Stock Overview

Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.

GNMSFā—PNK
HealthcareBiotechnology
$249.00
$0.45(0.18%)
U.S. Market opens in 7h 35m
Advertisement

Genmab A/S (GNMSF)

Meyka AI Score

Z

Key Financials

Market Cap15.3B
P/E Ratio18.63
EPS (TTM)$13.15
ROE0.15%
Fundamental Analysis

AI Price Forecasts

1 Month$288.49
3 Months$321.25
1 Year Target$237.46

GNMSF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Genmab A/S (GNMSF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 43.71, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $237.46.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 18.63 and a market capitalization of 15.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.18%
5-Day Change
-0.18%
1-Month Change
-3.98%
3-Month Change
-14.14%
6-Month Change
-21.20%
Year-to-Date (YTD) Change
-20.70%
1-Year Change
14.15%
3-Year Change
-35.53%
5-Year Change
-40.72%
All-Time (Max) Change
1496.15%

Contact Information

45 70 20 27 28
Kalvebod Brygge 43, Copenhagen, NaN, 1560

Company Facts

2,638 Employees
IPO DateJan 5, 2010
CountryDK
Actively Trading

Frequently Asked Questions